证券代码：301188 证券简称：力诺药包 公告编号：2025-074 债券代码：123221 债券简称：力诺转债 山东力诺医药包装股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据山东力诺医药包装股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日召开 的第四届董事会第十二次会议决议，公司董事会定于 2025 年 9 月 5 日召开 2025 年第二 次临时股东会。现将有关事项通知如下： 一、会议召开基本情况 章、规范性文件和《公司章程》的有关规定。 现场会议召开时间：2025 年 9 月 5 日（星期五）14:50 网络投票时间： 其中，通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时 间为：2025 年 9 月 5 日 9:15-9:25、9:30—11:30，13:00—15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为：2025 年 9 月 5 日 9:15-15:00。 （1）现场投票：股东本人出席现场会议或者通过授权他人出席现场会议； （2）网络投票：本次股东会将通过深圳证券交易所交易 ...

Group 1 - The company plans to purchase Directors, Supervisors, and Senior Management Liability Insurance (D&O Insurance) to enhance its risk management system and protect the rights of its executives and shareholders, especially minority investors [1][2] - The board of directors has proposed to authorize the management to handle the purchase of the D&O Insurance, including determining the insured parties, insurance company, compensation limits, premiums, and other related matters [2] - The proposal for the D&O Insurance was discussed in the board and supervisory meetings held on August 19, 2025, where all directors and supervisors abstained from voting due to being insured parties, leading to the proposal being submitted to the upcoming extraordinary general meeting for approval [1][2]

Summary of Key Points Core Viewpoint The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., has decided to change the use of part of the raised funds from its convertible bond issuance to better align with its current development needs and strategic planning. Group 1: Fundraising Overview - The company issued 5 million convertible bonds with a total fundraising amount of 500 million RMB, netting 491.44 million RMB after deducting fees [1][2] - The original project for the raised funds was the industrialization of lightweight pharmaceutical molded glass bottles, with a total investment of 641.87 million RMB [2][4] - As of August 10, 2025, 126.05 million RMB of the raised funds had been utilized, leaving an unused amount [2][4] Group 2: Change in Fund Usage - The company plans to reallocate 154 million RMB from the original project to two new projects: acquiring a 30% stake in Chuangyang Co. and the second phase of the high-end pharmaceutical packaging project [2][5] - The new projects include an investment of 84 million RMB for the acquisition and 70 million RMB for the high-end packaging project [2][5] Group 3: Rationale for Change - The original project faced delays due to late delivery of construction facilities and lengthy customer certification processes, leading to a reduced funding requirement [4][5] - The company received a government subsidy of 89.58 million RMB for the original project, further decreasing the need for raised funds [4][5] Group 4: New Investment Projects - The acquisition of a 30% stake in Chuangyang Co. aims to enhance the company's product offerings and market share in pharmaceutical packaging [5][8] - The second phase of the high-end packaging project focuses on RTU (Ready-to-Use) packaging and pre-filled syringes, with a total investment of 383.37 million RMB [9][10] - The project is expected to have a payback period of 6.82 years and an internal rate of return of 16.37% [9] Group 5: Strategic Importance - The new projects align with the growing demand for high-quality pharmaceutical packaging driven by trends in the pharmaceutical industry [10][11] - The company aims to transition from a traditional pharmaceutical glass manufacturer to a diversified high-end packaging solution provider [10][12] - The strategic shift is supported by national policies promoting the development of the pharmaceutical packaging industry [13][14] Group 6: Approval Process - The board of directors and the supervisory board have approved the change in fund usage, ensuring compliance with relevant regulations [16][17] - The independent directors also confirmed that the decision aligns with the company's interests and does not harm shareholder value [17][18]

山东力诺医药包装股份有限公司 第四届董事会独立董事 2025 年第五次专门会议审核意见 根据《中华人民共和国公司法》 《深圳证券交易所创业板股票上市规则》 《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律、法规和规范性文件以及《公司章程》的有关规定，山东力诺医药包装股份有 限公司（以下简称"公司"）独立董事召开了第四届董事会独立董事 2025 年第五 次专门会议，审议通过了《关于公司<2025 年半年度募集资金存放与使用情况的 专项报告>的议案》《关于变更部分募集资金用途的议案》《关于拟对外投资购买 股权的议案》 《关于购买董监高责任险的议案》 经核查，我们认为：本次交易是基于公司业务发展需要，为实现公司长远发 展战略规划而做出的整体安排，有利于整合公司与苏州创扬新材料科技股份有限 公司的资源和优势，实现资源共享、共同发展。本次交易风险可控，投资资金来 源于公司募集资金，不会影响公司生产经营活动和现金流的正常运转，不会对公 司未来财务及经营状况产生重大影响，不存在损害上市公司及股东利益的情形。 我们一致同意本次对外投资购买股权事项。 四、关于购买董监高责任险的审核意见 经核 ...

Summary of Key Points Core Viewpoint - The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., plans to establish a joint venture with its controlling shareholder, Linuo Group, to utilize idle land resources and leverage Linuo Group's expertise in park construction and management [1][2]. Group 1: Overview of Related Transactions - The joint venture, named Linuo Innovation Technology (Shanghe) Co., Ltd., will be established with Linuo Group holding 51% and the company holding 49% through land contributions valued at approximately RMB 45.41 million [1][4]. - This transaction is classified as a related party transaction due to Linuo Group being the controlling shareholder of the company [2]. - The board of directors approved the investment proposal on August 19, 2025, with independent directors also consenting, thus not requiring shareholder approval [2][8]. Group 2: Financial and Governance Structure - The company will contribute land valued at RMB 45.41 million, while Linuo Group will provide cash for its share [5]. - The governance structure of the joint venture will involve a board elected by shareholders, with the chairman also serving as the general manager [5]. Group 3: Purpose and Impact of the Joint Venture - The primary goal of the joint venture is to revitalize idle land resources and develop a "Science and Technology Innovation Center" [6]. - The collaboration is expected to enhance resource integration and expedite land development, aligning with the company's future growth needs [7]. Group 4: Compliance and Approval Process - The related party transaction has been reviewed and approved by the board and independent directors, adhering to relevant regulations and company policies [8]. - The total amount of related transactions with Linuo Group and its subsidiaries for the year to date is RMB 2.5151 million, excluding this transaction [7].

Core Viewpoint - The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., is changing the use of part of the raised funds from its convertible bond issuance to better align with its strategic development needs and improve fund utilization efficiency [2][19]. Summary by Sections Fundraising Overview - The company issued 5 million convertible bonds with a net fundraising amount of RMB 491.4447 million, after deducting underwriting fees [2][3]. - As of August 10, 2025, a total of RMB 126.0511 million has been invested from the raised funds, with the remaining amount stored in dedicated bank accounts [3][5]. Change in Fund Usage - The company plans to change the use of RMB 154 million from the "Lightweight Pharmaceutical Glass Bottle (Class I) Industrialization Project" to invest in two new projects: acquiring 30% equity in Suzhou Chuangyang New Materials Technology Co., Ltd. and the second phase of the high-end pharmaceutical packaging project [3][4]. - The new projects include an investment of RMB 84 million for the equity acquisition and RMB 154 million for the high-end packaging project [3][6]. Reasons for Change - The original project faced delays due to late delivery of construction facilities and longer customer certification cycles, leading to a reduced need for the originally planned funds [5][6]. - The company received a government subsidy of RMB 89.58 million, which decreased the funding requirement for the original project [5][6]. New Investment Projects - The acquisition of 30% equity in Suzhou Chuangyang New Materials is aimed at enhancing the company's product offerings and market share in pharmaceutical packaging [6][10]. - The second phase of the high-end pharmaceutical packaging project focuses on the production of Ready-to-Use (RTU) packaging and pre-filled syringes, with a total investment of RMB 383.3725 million, of which RMB 70 million will come from the raised funds [10][11]. Impact of Changes - The changes in fund usage are expected to enhance the company's operational efficiency and long-term benefits without adversely affecting its existing business or financial status [19][20]. - The company will implement strict internal and external supervision of the fund usage to ensure compliance with relevant regulations [20][21].

Core Viewpoint - Shandong Linuo Pharmaceutical Packaging Co., Ltd. reported a revenue of 499 million yuan and a net profit of 40.97 million yuan for the first half of 2025, while facing external pressures such as weak terminal demand and declining product prices. The company aims to stabilize operations, improve efficiency, and pursue expansion through both its core business and external acquisitions [1][5]. Group 1: Business Performance - The company achieved a total asset value of 2.537 billion yuan by the end of the reporting period [1]. - The production capacity of borosilicate pharmaceutical glass has been further enhanced, with the first kiln of the lightweight molded glass bottle project having been put into operation in February 2025 [1]. - The increase in production capacity is expected to meet the growing demand from downstream customers and expand the company's market share in the pharmaceutical packaging sector [1]. Group 2: Brand Development and Transformation - The company is accelerating its transformation towards self-owned brands, having established an e-commerce company in Hangzhou to promote its domestic brand "LEBOLEBO" and international brand "brohouse" [3]. - Since 2025, the company has been enhancing its internal design capabilities to launch fashionable glass products that cater to younger consumers, transitioning from an OEM to an ODM model [3]. Group 3: External Expansion and Strategic Investments - The company plans to invest in high-quality enterprises in the pharmaceutical packaging sector as part of its external development strategy for 2025, aiming to broaden its product range and provide one-stop procurement for pharmaceutical clients [3]. - The company has conducted assessments in regions such as Saudi Arabia, Brazil, and Southeast Asia, and signed a cooperation investment agreement with SANTISA in March 2025 [3]. Group 4: Joint Ventures and Acquisitions - The company announced a joint investment of 92.65 million yuan with Linuo Group to establish Linuo Innovation Technology (Shanghe) Co., Ltd., focusing on revitalizing idle land resources and creating a high-end pharmaceutical packaging industry platform [5][7]. - The company plans to acquire a 30% stake in Suzhou Chuangyang New Materials Technology Co., Ltd. for 84 million yuan, which will enhance its service capabilities by integrating plastic packaging materials with its existing glass offerings [7]. Group 5: Financial Health - The company reported a net cash outflow of 96.05 million yuan from operating activities due to increased raw material inventory and slower sales collection [8]. - The company maintains a cash reserve of 537 million yuan, which, along with unused fundraising and bank credit, is sufficient to cover convertible bond repayments, project construction, and acquisition funding needs [8]. - The debt-to-asset ratio stands at 37.1%, indicating a relatively low level compared to the industry, allowing for ample leverage for future expansion [9].

Core Viewpoint - Central state-owned enterprises (SOEs) play a crucial role as stabilizers in the national economy, particularly in technology-driven sectors, contributing to national security and economic development [1]. Group 1: Role of Central SOEs - Central SOEs, especially technology-oriented ones, are seen as leaders and innovators in driving national development and addressing major issues [1]. - The recent event "I am a Shareholder - Entering Central SOE Listed Companies" highlighted the importance of these companies in sharing their technological advancements and strategic developments with investors [1]. Group 2: R&D Investment and Innovation - Central SOEs have significantly increased R&D investments, mastering core technologies and enhancing production efficiency, which supports key industries [2]. - For instance, Changfei Fiber has invested over 5% of its annual sales revenue into technological innovation, while over the past five years, Yifang Communication has invested more than 20 billion yuan in R&D [2][3]. Group 3: Achievements in Technology - Yifang Communication has broken world records in the "three super" optical transmission field six times in five years, contributing to the construction of national backbone communication networks and 5G networks [3]. - Huachang Technology, under the China Weaponry Equipment Group, pivoted to produce medical supplies during the COVID-19 pandemic, showcasing its adaptability and commitment to innovation [3]. Group 4: Future Strategies and Goals - The emphasis on technology innovation is critical for achieving national strategic goals, with companies viewing themselves as integral to national development [4]. - Companies are focusing on integrating their strategies with national needs and industry trends, aiming to be leaders in their respective fields [4][5]. Group 5: Internationalization Efforts - Internationalization is becoming a key strategic focus for central SOEs, with companies like Yifang Communication and Changfei Fiber planning to expand their overseas operations, particularly along the "Belt and Road" initiative [6].

Group 1 - The core viewpoint of the news is the establishment of a joint innovation laboratory between Tuokene Technology and Geely Automobile Research Institute to address the bottlenecks in the COC industry and promote the development of automotive optical materials [1][2] - Tuokene Technology has achieved continuous stable production of COC with a newly built production line of 3,000 tons per year, overcoming challenges in the entire supply chain from raw material supply to processing [2] - The collaboration aims to fill the technological gap in high-end optical materials for vehicles, which is crucial for the "visual system" in smart cars, impacting user experience and driving safety [2][3] Group 2 - Tuokene Technology's products, such as "TAMT," have achieved domestic substitution in various fields including optical lenses, biomedical applications, and smart cockpits [2] - The partnership with Shanghai Haishun New Material Co., Ltd. in the life sciences sector highlights the importance of technological breakthroughs and industry chain collaboration [2] - The use of COC in pharmaceutical packaging addresses issues such as low barrier material usage and poor stability, ensuring the safety and stability of drug packaging [3]

力诺药包（301188）(301188.SZ)公告，公司股东复星惟实及其一致行动人复星惟盈拟减持公司股份不 超697.87万股，占公司总股本比例为3.0000%;公司原董事、股东徐广成拟减持公司股份不超142.86万 股，占公司总股本比例为0.6141%。 ...